NanoPass Intradermal Injection Platform Proven to Support COVID-19 Vaccine Antibodies Using 1/15 of the Dose Reports China Institute of Medical Biology

NES ZIONA, Israel and Shanghai, China, February 7, 2022 /PRNewswire/ — Intradermal COVID vaccination studies are emerging as part of a global effort to increase available doses by harnessing skin immunity to reduce the dose required for effective vaccination. In a landmark study published recently by scientists at IMB[1], subjects were immunized twice with IMB’s inactivated SARS-CoV-2 vaccine intramuscularly. Approximately six months later, 20 participants randomly received 1/15 (™600 device. Significant increases in antibody levels were demonstrated one week and 2 months after injection (X8-10 and X12.5-97 from baseline, respectively). Six months later, antibody levels were reduced but remained significantly higher than baseline (X8.5-12). These results showed that the 3rd intradermal boost provided robust and sustained immunogenicity (>6 months) with favorable safety (no fever and only mild redness and swelling at the injection site).

CEO of NanoPass, Dr. Yotam Levin said: “We commend Chinese researchers for their continued pioneering work during COVID-19, with the goal of developing, evaluating and improving vaccines against this horrific pandemic. Excitingly, the study design n used only 1/15 of the dose, potentially allowing a 15-fold increase in available doses and demonstrated durability of response for at least six months. The study was conducted with the MicronJet600 injection device, which is registered in China and most major markets, and which provides consistent intradermal inoculation.”

This step is a joint effort between NanoPass and YNC, who supported IMB. YNC has been working hard to promote NanoPass intradermal delivery platform in China and this cooperation is a major step on the way to helping China fight against COVID-19.

CEO of YNCNi Jian says: China has made significant progress in the fight against COVID, however, antibodies drop to a significantly low level six months after vaccination, providing a hotbed for the recurrence of the pandemic. This means that finding a way to improve antibody levels and maintain such high levels for longer becomes critical. Thanks to the reliability and consistency of MicronJet600 for intradermal injections, IMB, with our support, found a method to significantly increase the antibody level (from 8 to 97 times) and maintain it at a high level for at least six months. This milestone discovery and follow-up study should provide important weapons for global victory over COVID-19.

About NanoPass:
NanoPass is a pioneer in the development and commercialization of microneedle-based delivery platforms for aesthetics, vaccines and more. It is supported by extensive clinical data and approved for delivery of any substance or drug below the surface of the skin that is approved for this route of administration. Visit

About YNC:
YNC Medical is committed to integrating advanced products and technologies from East and West, and creating value for the whole industrial chain through the upgrading of key products. As NanoPass’ first partner in the medical market in China, over the past few years, YNC has worked with KOLs in more than 20 provinces, and conducted training and academic communication with more than 10,000 doctors and medical workers. At the same time, we have assisted several research institutions in relevant academic research. By implementing the stable intradermal injection performance of MicronJet600, we aim to bring about a revolutionary change in the areas of skin testing for allergies and tuberculosis and primarily for vaccines, including COVID-19.

[1] Fan S, et al. “Enhanced immunity elicited by intradermal inoculation in individuals vaccinated with the inactivated SARS-CoV-2 vaccine”. Vaccine. 2021 Nov 26;39(48):6980-6983.

View original content: – reports-chinese-institute-of-medical-biology-301476501.html


Comments are closed.